Emerging strategies in infectious diseases: New carbapenem and trinem antibacterial agents

Drugs

Volumn 61, Issue 5, 2001, Pages 553-564

  Sader, Helio S ^a   Gales, Ana C ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 HYDROXYETHYL) 2 [2 (3 METHANESULFONYLAMINO 1 PROPENYL) 4 PYRROLIDINYLTHIO] 1 METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; AMINOACYLASE; BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM; CILASTATIN; CILASTATIN PLUS IMIPENEM; ERTAPENEM; FROPENEM; IMIPENEM; LENAPENEM; MEROPENEM; PANIPENEM PLUS BETAMIPRON; SANFETRINEM; THIENAMYCIN; TRINEM DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; CHEMICAL MODIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; NEPHROTOXICITY; NONHUMAN; REVIEW;

EID: 0035019853     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161050-00001     Document Type: Review

References (85)

1. 1. Livermore DM, Williams DJ. β-lactams: mode of action and mechanism of bacterial resistance. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1996: 502-78
2. 2. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimcrobial agents. N Engl J Med 1991; 324: 601-12
3. 3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33
4. 4. Philippon A, Labia R, Jacoby GA. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6
5. 5. Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998 Jul; 31: 461-6
6. 6. Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. Antimicrob Agents Chemother 1983; 12 D Suppl.: 1S-35S
7. 7. Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30: 129-34
8. 8. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994 Mar; 38: 547-57
9. 9. Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11: 93-100
10. 10. Coulton S, Hunt E. Recent Advances in the chemistry and biology of carbapenems antibiotics. In: Ellis GP, Lumskobe DK, editors. Progress in medicinal chemistry. Amsterdam, Elsevier Science BV, 1996: 99-145
11. 11. Andrus A, Baker FA, Bouffard FA, et al. Structure-activity relationships among some totally synthetic carbapenems. In: Brown AG, Roberts SM, editors. Recent advances in the chemistry of β-lactams. London: The Royal Society of Chemistry, 1984: 86-99
12. 12. Christensen BG. Structure activity relationships in beta-lactam antibiotics. In: Salton MEJ, Schockman GD, editors. Beta-lactam antibiotics. Mode of action, new development, and future prospects. London: Academic Press, 1981: 101-25
13. 13. Miyadera T, Sugimura Y, Hashimoto T, et al. Synthesis and in vitro activity of a new carbapenem, RS-533. J Antibiot 1983 Aug; 36: 1034-9
14. 14. Edwards JR, Betts MJ. Carbapenems: the pinnacle of the β-lactam antibiotics or room for improvement. J Antimicrob Chemother 2000 Jan; 45: 1-4
15. 15. Tanimura H, Ochiai M, Sugimoto Y, et al. Tissue concentration and clinical efficacy of panipenem/betamipron in surgical infections. Chemotherapy Tokyo 1991; 39: 585-95
16. 16. Edwards JR, Turner PJ, Wannop C, et al. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase. I. Antimicrob Agents Chemother 1989 Feb; 33: 215-22
17. 17. Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase. I. Antimicrob Agents Chemother 1990 June; 34: 994-1000
18. 18. Petersen PJ, Jacobous NV, Weiss WJ, et al. In vitro and in vivo activity of LJC10,627, a new carbapenem antibiotic with stability to dehydropeptidase. I. Antimicrob Agents Chemother 1991 Jan; 35: 203-7
19. 19. Neu HC, Gu JW, Fang W, et al. In vitro activity and β-lactamase stability of LJC 10,627. Antimicrob Agents Chemother 1992 Jul; 36: 1418-23
20. 20. Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 1993 Sep; 37: 2009-16
21. 21. Clarke AM, Zemcov SJV. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993; 12: 377-84
22. 22. Catchopole CR, Wise R, Thomber D, et al. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992 Sep; 36: 1928-34
23. 23. Sader HS, Jones RN. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem, and other broad-spectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993; 12: 384-91
24. 24. Nord CE, Lahnborg G. Biapenem versus imipenem in the treatment of experimental intra-abdominal infections. J Chemother 1995 Feb; 7: 42-4
25. A, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993 Feb; 37: 199-202
26. 26. Hikida M, Kawashima K, Nishiki K, et al. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992 Feb; 36: 481-3
27. 27. Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998 Jun; 42: 1433-6
28. 28. Toynaga Y, Ishihara T, Tezuka T, et al. Pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field [in Japanese]. Jpn J Antibiot 1994 Dec; 47: 1691-705
29. 29. Brismar Bo, Åkerlund JE, Sjöstedt S, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intraabdominal infections: report from a Swedish Study Group. Scand J Infect Dis 1996; 28: 507-12
30. 30. Ohtake N, Okamoto O, Mitomo R, et al. 1β-methyl-2-(5-sustituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and antibacterial activity of BO-2727 and its related compounds. J Antibiot 1997 Jul; 50: 598-613
31. 31. Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother 1996; 37: 1034-6
32. 32. Hashizume T, Nakamura K, Nakagawa S. Affinities of BO-2727 for bactericidal penicillin-binding proteins and morphological change of Gram-negative rods. J Antibiot 1997 Feb; 50: 139-42
33. 33. Kato Y, Otsuki M, Nishino T. Antibacterial properties of BO-2727, a new carbapenem antibiotic. J Antimicrob Chemother 1997; 40: 195-203
34. 34. Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem-and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiot 1997 Feb; 50: 135-8
35. 35. Mikamo H, Kawazoe K, Izumi K, et al. In vitro and in vivo antibacterial of a new carbapenem BO-2727 for use in obstetrics and gynecology. Chemother 1998; 44: 12-6
36. 36. Miyauchi M, Endo R, Hisaoka M, et al. Synthesis and structure-activity relationships of a novel oral carbapenem, CS-834. J Antibiot 1997 May; 50: 429-39
37. 37. Miyauchi M, Kanno M, Kawamoto I. A novel oral carbapenem CS-834: chemical stability of pivaloyloxymethyl esters of carbapenems and cephalosporins in phosphate buffer solution. J Antibiot 1997 Sep; 50: 794-5
38. 38. Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivamecillinam therapy. Lancet 1989 Aug; 2: 469-73
39. 39. Umemura K, Ikeda Y, Kondo K, et al. Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1997 Dec; 41: 2664-9
40. 40. Sakagawa E, Otsuki M, Ou T, et al. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem. J Antimicrob Chemother 1998; 42: 427-37
41. 41. Fukuoka T, Ohya S, Utsui Y, et al. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother 1997 Dec; 41: 2652-63
42. 42. Yamaguchi K, Domon H, Miyazaki S, et al. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob Agents Chemother 1998 Mar; 42: 555-63
43. 43. Fukuoka T, Kawada H, Kitayama A, et al. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob Agents Chemother 1998 Jan; 42: 23-7
44. 44. Gill CJ, Jackson JJ, Gerckens LS, et al. In vitro activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother 1998 Aug; 42: 1996-2001
45. 45. Fuchs PC, Barry AL, Brown SD. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and a provisional interpretative criteria for disc tests. J Antimicrob Chemother 1999; 43: 703-6
46. 46. Odenholt I, Löwdin E, Cars O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 1998 Sep; 42: 2365-70
47. 47. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens. Antimicrob Agents Chemother 1997 Aug; 41: 1830-1
48. 48. Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999 May; 43: 1170-6
49. 49. Sundelof JG, Hajdu R, Gill CJ, et al. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother 1997 Aug; 41: 1743-8
50. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1996: 122
51. 51. Sturm A, Pachon-Diaz J, Bach M, et al. Phase IIA randomized, double-blind, multicenter study of MK-826 versus ceftriaxone sodium in the treatment of serious lower respiratory tract infections: a preliminary analysis [abstract]. Clin Infect Dis 1998 Oct; 27: 952
52. 52. Kim SH, Kim WB, Lee MG. Stability, tissue metabolism, tissue distribution, and blood partition of DA-1131, a new carbapenem. Res Commun Mol Pathol Pharmacol Dec 1995; 90: 347-62
53. 53. Kim SH, Kwon JW, Lee MG. Pharmacokinetics and tissue distribution of a new carbapenem. DA-1131, after intravenous administration to mice, rats, rabbits, and dogs. Biopharm Drug Dispos 1998; 19: 219-29
54. 54. Kim SH, Kim WB, Lee MG. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. Antimicrob Agents Chemother 1999 Jan; 43: 96-9
55. 55. Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits, and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 1998; 19: 231-5
56. 56. Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenm. Antimicrob Agents Chemother 1998 Jan; 42: 94-9
57. 57. Tanaka M, Hohmura M, Nishi T, et al. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob Agents Chemother 1997 Jun; 41: 1260-8
58. 58. Ohba F, Nakamura-Kamijo M, Watanabe N, et al. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother 1997 Feb; 41: 298-307
59. 59. Kohler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999 Feb; 43: 424-7
60. 60. Yang Y, Testa RT, Bhachech N, et al. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother. 1999 Dec; 43: 2904-9
61. 61. Weiss WJ, Mikels SM, Petersen PJ, et al. In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems. Antimicrob Agents Chemother 1999 Mar; 43: 460-4
62. 62. Matsumara N, Minami S, Mitsuhashi S. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to β-lactamase. J Antimicrob Chemother 1997; 39: 31-4
63. 63. Modugno ED, Erbetti I, Ferrari L, et al. In vitro activity of the tribactam GV 129606 against Gram-positive, Gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother 1994 Oct; 38: 2362-8
64. 64. Johnson AP, Warner M, Speller DC. In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus. J Antimicrob Chemother 1998 Nov; 42: 643-6
65. 65. Sifaoui F, Varon E, Kitzis MD, et al. In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998 Jan; 42: 173-5
66. 66. Modugno ED, Broggio R, Erbetti I, et al. In vitro and in vivo antibacterial activities of GV 129606, a new broad-spectrum trinem. Antimicrob Agents Chemother 1997 Dec; 41: 2742-8
67. 67. Wise R, Andrews JM, Brenwald N. In vitro activity of the tricyclic β-lactam GV 104326. Antimicrob Agents Chemother 1996 May; 40: 1248-53
68. 68. Singh KV, Coque TM, Murray BE. In vitro activity of the trinem sanfetrinem (GV 104326) against gram-positive organisms. Antimicrob Agents Chemother 1996 Sep; 40: 2142-6
69. 69. Doern GV, Pierce G, Brueggemann AB. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996 Sep; 26: 39-42
70. 70. Andrews JM, Hadley N, Brenwald NP, et al. Susceptibility testing of fastidious organisms. J Antimicrob Chemother 1997 Mar; 39: 436-7
71. 71. Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1997 Oct; 41: 2173-6
72. 72. Spangler SK, Jacobs MR, Appelbaum PC. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother 1997 Jan; 41: 148-55
73. 73. Betriu C, Gomez M, Palau ML, et al. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother 1999 Sep; 43: 2320-2
74. 74. Babini GS, Yuan M, Livermore DM. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams. Antimicrob Agents Chemother 1998 May; 42: 1168-75
75. 75. Chen HY, Livermore DM. Comparative activity of cefepime against chromosomal β-lactamase inducibility mutants of gram-negative bacteria. J Antimicrob Chemother 1993; 32 Suppl. B: 63-74
76. 76. Tullio V, Palarchio AI, Bonino A, et al. Sub-MICs of sanfetrinem promote the interaction of human polymorphonuclear granulocytes with a multiply resistant strain of Klebsiella pneumoniae. J Antimicrob Chemother 1998 Aug; 42: 249-52
77. 77. Cuffini AM, Tullio V, Bonino A, et al. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1998 Jul; 42: 1745-50
78. 78. Tamura S, Miyazaki S, Tateda K, et al. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic. Antimicrob Agents Chemother 1998 Jul; 42: 1858-61
79. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washinton, DC: American Society for Microbiology, 1994: 129
80. 80. Wise R, Andrews JM, Da Ros L, et al. A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326). Antimicrob Agents Chemother 1997 Aug; 41: 1761-4
81. 81. Sader HS, Pfaller MA, Tenover FC, et al. Evaluation and characterization of multiresistant Enterococcus faecium from twelve U.S. medical centers. J Clin Microbiol 1994 Nov; 32: 2840-2
82. 82. Jones RN, Pfaller MA. Bacterial resistance: a worldwide problem. Diagn Microbiol Infect Dis 1998 Jun; 31: 379-88
83. 83. Sader HS, Mendes CF, Pignatari AC, et al. Use of macrorestriction analysis to demonstration interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil. Clin Infect Dis 1996 Sep; 23: 631-4
84. 84. Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility of patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: results from the SENTRY Antimicrobial Surveillance Program (1997). Diagn Microbiol Infect Dis 1998 Dec; 32: 289-301
85. 85. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999 Jun; 43: 1379-82